POSTER ABSTRACTS
July 25th- 28th, 2012 | Rio de Janeiro, Brazil
Co-Organizers
The Brazilian Society for Cell Biology (SBBC)
Executive committee
President
Vice-President
Directors
Secretary
Treasurer
Wilson Savino - Fiocruz, Rio de Janeiro
Vilma R Martins – Hospital A C Camargo, São Paulo
Marimélia Porcionatto - UNIFESP, São Paulo
Patrícia Gama - USP, São Paulo
Flavia A C Gomes - UFRJ, Rio de Janeiro
Irene Yan - USP, São Paulo
Marinilce F Santos - USP, São Paulo
The International Federation for Cell Biology (IFCB)
President
Vice-President
Secretary General
Denys Wheatley - Aberdeen, Scotland, UK
Cheng-Wen Wu - NHRI, Taiwan
Hernandes F Carvalho - UNICAMP, Brazil
Financial Support
FCW
Fundação
Conrado
Wessel
Institutional Support
2
Organizing Committee
Co-Chairs
Hernandes F Carvalho (State University of Campinas)
International Federation for Cell Biology IFCB
Patrícia Gama (University of São Paulo)
Brazilian Society for Cell Biology SBBC
Brazilian Committee
Estela Bevilacqua (University of São Paulo)
Flávia Gomes (Federal University of Rio de Janeiro)
Irene Yan (University of São Paulo)
Marinilce F Santos (University of São Paulo)
Marimélia Porcionatto (Federal University of São Paulo)
Milton Moraes (FIOCRUZ)
Thereza Christina Barja-Fidalgo (University of Rio de Janeiro)
International Contacts
Europe: Anne Eichmann (College de France, France; Yale University, USA)
US: Bechara Kachar (NIDCD, NIH, USA)
Latin America: Gabriel Rabinovitch (Buenos Aires University, Argentina)
Asia: Ken Wen Wu (NHRI, Taiwan)
Australia: James Armitage (Monash University, Australia)
Scientific Committee
Bechara Kachar
Betina Malnic
Carla Collares
Carlos Ramos
Célia Regina Garcia
Celuta Sales Alviano
Cláudia Mermelstein
Claudio Simon
Constance Oliver
Edna Kimura
Emer Suavinho Ferro
Enilza Espreafico
Estela Bevilacqua
Fábio Papes
Fernando Costa e Silva Filho
Flávia CA Gomes
Glaucia Santelli
Gustavo Amarante Mendes
Hernandes F Carvalho
Hugo Armelin
Irene Yan
Ivarne Tersariol
Jorg Kobarg
José Garcia Abreu
José Mauro Granjeiro
José Xavier Neto
Klaus Hartfelder
Luiz Renato França
Manoel Costa
Mari Sogayar
Maria Célia Jamur
Maria Isabel Cano
Marimélia Porcionatto
Marinilce F Santos
Marlene Benchimol
Mirian Jasulionis
3
Nadja Souza-Pinto
Paolo Meda
Patrícia Bozza
Patrícia Gama
Renata Pasqualini
Ricardo Guellerman
Roger Chammas
Ruy Jaeger
Sang Won Han
Sérgio Schenckman
Silvana Allodi
Vilma R Martins
Vivaldo Moura Neto
Wadih Arap
Wanderley de Souza
Wilma Kempinas
Wilson Savino
Presentation guidelines
Poster Sessions will be held at 1st and 2nd floors (Room 203) and will be organized
according to the different areas. Please check your Board ID above.
Poster Session I: Thursday, July 26th
Set up: Wednesday 15h00- 17h00 and Thursday 9h00- 9h30
Tear down: until 15h30
Poster Session II: Friday, July 27th
Set up: Thursday 16h30 -18h00 and Friday 9h00- 9h30
Tear down: 16h00- 16h30
Author presentation hour for both sessions:
11h45- 12h45 even numbers
12h45-13h45- odd numbers
Poster numbers will identify the boards. Tapes and hangers should be brought to the
area by presenters. The Organizing Committee will not provide these items and will not
collect and keep Posters that are left on the Boards.
We will invite our speakers to select and nominate three best posters according to their
expertise. Winners and prizes will be announced during the closing cerimony
4
B207
Analysis of the leptin signaling pathway components of thyroid papillary carcinoma of
children and adolescents by immunostaining
Authors: Mario Lucio Cordeiro Araujo Junior; Viviane Younes-Rapozo; Nayara PeixotoSilva; Patrícia Lisboa; Elaine de Oliveira; Rossana Corbo; Marcelli Gatto; Albanita Viana
de Oliveira ; Egberto Gaspar de Moura
Children and adolescents account for 2% of the thyroid carcinoma cases. The prognosis
of papillary thyroid carcinoma is excellent with survival rates over 95% as long as they
are diagnosed in early stages. Leptin can act as a mitogenic and angiogenic factor and
there is a greater expression of leptin and/or its receptor (ObR) in several types of
tumors, including papillary thyroid carcinoma in adults. Here, we evaluated the
expression/distribution of components of leptin signaling cascade in samples of papillary
carcinoma of children and adolescents.
Histological sections of 53 patients with papillary thyroid carcinoma of National Cancer
Institute – INCA (CE0029.0.007.000-11) were done for diagnosis review and
confirmation of the papillary carcinoma, observing the presence of non-neoplastic
adjacent thyroid tissue for comparison. Four samples were analyzed by
immunofluorescence using the antibodies anti-ObR, anti-pJAK-2 and anti-pSTAT3.
On the non-neoplastic tissue, the pattern of immunostaining for ObR, pJAK-2 and
pSTAT3 was in a punctiform and perinuclear shape with a continuous and more
homogeneous distribution along the membrane. In the papillary carcinoma, we
observed a heterogeneous pattern with a stronger or concentrated immunoreactivity in
certain regions, facing the fibrovascular core of the neoplastic papillas.
We have shown that the leptin pathway displays a differentiated distribution on the
papillary carcinoma of children and adolescents, facing the fibrovascular core,
suggesting that leptin can contribute to tumoral growth and that the signaling study can
help in the diagnosis and prognosis of the disease.
Support: FAPERJ, CAPES, CNPq.
Authors:
1-Mario Lucio Cordeiro Araujo Junior, [email protected] . Adress: Rua
Capitão Cesar de Andrade, 168/505 Leblon, Rio de Janeiro/RJ CEP 22431-010.
UERJ/INCA.
(21)-87576760
2-Viviane Younes-Rapozo, [email protected], UERJ
3-Nayara Peixoto-Silva, [email protected], UERJ
4- Elaine de Oliveira, [email protected], UERJ
5-Patrícia Cristina Lisboa, [email protected], UERJ
6-Rossana Corbo, [email protected], INCA
7-Marcelli Gatto, [email protected], INCA
8-Albanita Viana de Oliveira, [email protected], UERJ
9-Egberto Gaspar de Moura, [email protected], UERJ
B208
Apoptosis induction by a new derivative of podophyllotoxin in HL-60 cells
Faheina-Martins, G.V.1; Silveira, A.L1; Dantas, B.B. 1; Araújo, D.A.M1.
1 - Laboratório de Biotecnologia Celular e Molecular, Centro de Biotecnologia, UFPB,
João Pessoa – PB, Brasil
e-mail: [email protected]
Celular: (83) 87175879 ou (83) 9993-2568
Fontes de Financiamento: CNPq
Background: The suppression of apoptotic mechanisms is involved both in the process
of tumorigenesis and maintenance of the malignant phenotype as in the development
of drug resistance. Therefore, the development of compounds that induce apoptosis is
one of the therapeutic strategies in the field of oncology. Aim: In this work, the
cytotoxic effect of a new podophyllotoxin derivative was evaluated on HL-60 cell line.
Methodology: To assess the type of cell death induced in HL-60, cells were incubated
with the derivative A98 (4, 6 and 8 μM) for 1, 3, 6 and 12 hours. Etoposide (5 μM) was
used as a positive control. Flow cytometry was performed for detection of
phosphatidilserine exposure, determination of mitochondrial membrane potential and
estimation of caspases -8, -9, and -3 activity. DNA fragmentation was qualitatively
analyzed by gel electrophoresis. The expression of bcl-2 was evaluated by western blot.
Results: Death promoted by derivative A398 was time and concentration-dependent.
After a period of 1 hour, there was an increase in mitochondrial membrane
depolarization and inhibition of the expression of Bcl-2. After 3 hours, derivative A398
induced externalization of phosphatidylserine, promoted significant activation of
caspases -8, -9 and -3 and induced maximal DNA fragmentation in 6 hours. These
effects are much faster than the one promoted by etoposide. Conclusions: Consistent
with these observations, the drug could effectively induce early apoptosis in leukemia
cells, through the activation of the extrinsic and intrinsic pathways of death.
B209
A new Fab inhibits cell proliferation in MCF7 breast carcinoma cells
B210
Induction of Apoptosis in human lung alveolar carcinoma epithelial cells
(A549) by the metallic complex cis-Tetraammine(oxalato)Ruthenium(III)
Dithionate
Thaise G. Araújo1; Cláudia M. Rodrigues1; Bruna F. Matias1; Yara C.P. Maia1, Angela A.S.
Sena1; Carolina Fernandes Reis2; Carlos Ueira-Vieira1; Luiz R Goulart1
1
Laboratory of Nanobiotechnology, Institute of Genetics and Biochemistry – Federal
University of Uberlandia.
2
Laboratory of Cancer Molecular Genetics, Faculty of Medical Sciences – UNICAMP,
Address: 126, Tessália Vieira de Camargo St.,Zip code: 13083-887. Campinas-SP, Brazil.
TGA: [email protected]
CMR: [email protected]
BFM: [email protected]
YCPM: [email protected]
AASS: [email protected]
CFR: [email protected]
CUV: [email protected]
LRG: [email protected]
Abstract
Breast cancer is the most frequent malignant tumor of women in North America, is the
second leading cause of death, after lung cancer and the parameters currently available
are not sufficient to capture its individual complexity. However, a heterogeneous
disease, encompassing a wide variety of pathological entities in which 40% of the
patients still succumb, highlights the need for new therapeutic strategies and
identification of new targets. We have constructed and selection a FabC4 recombinant
antibody by phage display in search for antigen-specific binding without cross-reactivity,
unequal expression of genes repertoire and yielding new applications in diagnosis and
therapy. The human breast carcinoma cell line MCF7 was established to elucidate the
functional role of FabC4. We carried out cell viability assay (MTT), Immunofluorescence
and Proliferation analysis by flow cytometry, using the follow concentrations of the
antibody: 0.87uM, 1.75uM, 3.5uM and 5.0uM. Confocal microscopy images revealed
that FabC4 bounded to MCF7 cells. Under the experimental conditions used, the FabC4
did not influence cell growth but inhibit cell proliferation when used 5.0uM of the
antibody. Our results suggest that FabC4 recognize a cytoplasmatic antigen which
influences of cell division. This Fab marker selected by phage display in this investigation
may be used in breast cancer therapy. Further analysis in other cells lines is necessary to
elucidate the functions of this potential antibody marker for breast cancer diagnosis and
treatment.
Financial support: CAPES, CNPq, FAPEMIG
89
ELISÂNGELA DE PAULA SILVEIRA-LACERDA1; FLÁVIA DE CASTRO PEREIRA1, ALINY
PEREIRA DE LIMA1, WANESSA CARVALHO PIRES1, CESAR AUGUSTO SAM TIAGO
VILANOVA-COSTA1
1
Laboratório de Genética Molecular e Citogenética, Instituto de Ciências Biológicas,
UniversidadeFederal de Goiás - UFG, Goiânia, Goiás, Brazil.
* [email protected]
First-line treatment for patients with advanced non-small cell lung cancer (NSCLC)
includes platinum compounds such cisplatin [cis-diamminedichloroplatinum(II)] and its
analogues carboplatin and oxaliplatin. Ruthenium complexes have shown potential
utility in chemotherapy. In the present work we studied the cytotoxic activity, cell cycle
arrest and the induction of apoptosis of the compound of cisTetraammine(oxalato)Ruthenium(III) Dithionate against human lung carcinoma (A549)
and normal human fetal lung fibroblast (MRC-5) cell lines. Results showed that this
Ruthenium(III) complex causes a significant reduction of proliferation of A549 cells with
viabilities ranging from 55.5% to 24.6% when treated with 40 µM for 24 and 48h; and
32% to 18.2% when treated with 150 µM for 24 and 48h. This complex induced a
moderate (31.9% and 39.6% for concentrations 10 and 40 µM, respectively) to high
degree (74% for concentration 150 µM) of cytotoxic activity against A549 cells (IC50=
33.72 µM). On the other hand, the normal lung fibroblast MRC-5 did not show
significant reduction proliferation in the presence of the Ruthenium(III) complex. Even
when treated with higher concentrations of the complex for 48 hours, MRC-5 cells
showed viabilities ranging from 85% to 78,4% for 40 µM and 150 µM, respectively. Cell
cycle analysis showed that the Ruthenium(III) complex led to an accumulation of A549
cells in G1 phase and increased Sub-G1. In addition, treatment with this complex
induced apoptosis, as observed by the increased numbers of Annexin V-positive cells
and increased mRNA expression of caspase-3.
Keywords: cis-Tetraammine(oxalato)Ruthenium(III) Dithionate; citotoxic activity; A549;
MRC-5; Lung cancer; apoptosis.